PDF herunterladen
Aktuelle Kardiologie 2015; 4(2): 114-119
DOI: 10.1055/s-0035-1545811
Übersichtsarbeit
Georg Thieme Verlag KG Stuttgart · New York

Medikamentöse Rhythmuskontrolle und orale Antikoagulation bei Patienten mit Vorhofflimmern: Bedeutung pharmakokinetischer Interaktionen für die klinische Praxis

Pharmacological Rhythm Control and Oral Anticoagulation in Patients with Atrial Fibrillation: Relevance of Pharmacokinetic Interactions for Clinical Practice
T. Klingenheben
1   Praxis für Kardiologie/Ambulante Herzkatheterkooperation Bonn, Bonn
,
J. Ruef
2   Kardiocentrum Frankfurt, Klinik Rotes Kreuz, Frankfurt am Main, Deutschland
,
C. Hammerstingl
3   Medizinische Klinik II, Universitätsklinikum Bonn, Deutschland
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
14. April 2015 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Neben der Katheterablation/Pulmonalvenenisolation hat auch die pharmakologische Therapie des Vorhofflimmerns in den letzten Jahren erhebliche Fortschritte erfahren. Einerseits ist die orale Antikoagulation durch Einführung der direkten oralen Antikoagulanzien (DOAKs) bereichert worden. Andererseits ist durch die Zulassung von Dronedaron das Arsenal der spezifisch-antiarrhythmischen Pharmakotherapie erstmals seit über 25 Jahren durch eine neuartige Substanz erweitert worden. Bei der Kombination der „modernisierten“ Therapieoptionen sind allerdings Wechselwirkungen und Kontraindikationen zu beachten. Die vorliegende Arbeit fasst die pharmakokinetischen Besonderheiten der potenziell für Interaktionen infrage kommenden Substanzen zusammen und versucht, Empfehlungen für die klinische Anwendung zu geben.

Abstract

Recently, progress has been achieved with regard to pharmacologic management of atrial fibrillation. First, oral anticoagulation has become a sophisticated therapeutic field with the advent of new direct oral anticoagulants (DOACs). Secondly, dronedarone has been approved as the first new antiarrhythmic drug in Europe for more than 25 years. However, with combination therapy including “modernised” therapeutic options important drug-drug interactions call for awareness. The present review summarizes the pharmacologic properties of the new drugs and tries to give recommendations with regard to clinically useful drug-drug combinations.

Schlüsselwörter

Vorhofflimmern - DOAKs - Antiarrhythmika - Interaktionen - P-Glykoprotein - CYP3A4

Key words

Atrial fibrillation - direct oral anticoagulants (DOAC) - antiarrhythmic drugs - drug–drug interactions - P-glycoproteine - CYP3A4
 

  • Literatur

  • 1 Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151
    CrossrefPubMedGoogle Scholar
  • 2 Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891
    CrossrefPubMedGoogle Scholar
  • 3 Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992
    CrossrefPubMedGoogle Scholar
  • 4 Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104
    CrossrefPubMedGoogle Scholar
  • 5 Camm AJ, Kirchhof P, Lip GYH et al. ESC Task Force. Guidelines for the management of atrial fibrillation. Eur Heart J 2010; 31: 2369-2429
    CrossrefPubMedGoogle Scholar
  • 6 Camm AJ, Lip GYH, De Caterina R et al. ESC Task Force. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747
    CrossrefPubMedGoogle Scholar
  • 7 Heidbuchel H, Verhamme P, Alings M et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651
    CrossrefPubMedGoogle Scholar
  • 8 Rodriguez I, Abernethy DR, Woosley RL. P-glycoprotein in clinical cardiology. Circulation 1999; 99: 472-474
    CrossrefPubMedGoogle Scholar
  • 9 Wessler JD, Grip LT, Mendell J et al. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol 2013; 61: 2495-2502
    CrossrefPubMedGoogle Scholar
  • 10 (a – c) Fachinformationen (a) Pradaxa®, Boehringer, Stand 6/2014; (b) Xarelto®, Bayer, Stand 7/2014; (c) Eliquis©, Bristol-Myers Squibb & Pfizer, Stand 7/2014.
    PubMedGoogle Scholar
  • 11 Kerin NZ, Blevins RD, Goldman L et al. The incidence, magnitude, and time course of the amiodarone-warfarin interaction. Arch Intern Med 1988; 148: 1779-1781
    CrossrefPubMedGoogle Scholar
  • 12 McDonald MG, Au NT, Wittkowsky AK et al. Warfarin-amiodarone drug-drug interaction: determination of [I]u/KI,U for amiodarone and its plasma metabolites. Clin Pharmacol Ther 2012; 91: 709-717
    CrossrefPubMedGoogle Scholar
  • 13 Hohnloser SH, Crijns HJ, van Eickels M et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 3660: 668-678
    PubMedGoogle Scholar
  • 14 Pogge EK, Haber SL. Elevated International normalized ratio (INR) associated with use of dronedarone and warfarin. Ann Pharmacother 2011; 45: e46
    CrossrefPubMedGoogle Scholar
  • 15 Reiffel JA. An important drug interaction between dronedarone and warfarin that may be extrapolated to other drugs that can alter gastrointestinal function. Am Heart J 2011; 161: e5
    CrossrefPubMedGoogle Scholar
  • 16 Le Heuzey JY, De Ferrari GM, Radzik D et al. A short-term randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010; 21: 597-605
    CrossrefPubMedGoogle Scholar
  • 17 Brunet A, Hermabessiere S, Benain X. Pharmacokinetic and pharmacodynamic interaction of dronedarone and dabigatran in healthy subjects (abstr. P3566). Eur Heart J 2011; 32: 618-619
    CrossrefPubMedGoogle Scholar
  • 18 Dabigatran FDA briefing document. Im Internet: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226009.pdf Stand: 25.03.2015
    PubMedGoogle Scholar
  • 19 Liesenfeld KH, Lehr T, Dansirikul C et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011; 9: 2168-2175
    CrossrefPubMedGoogle Scholar
  • 20 Gandhi PK, Gentry WM, Bottorff MB. Dabigatran-dronedarone interaction in a spontaneous reporting system. J Am Pharm Assoc 2013; 53: 414-419
    CrossrefPubMedGoogle Scholar
  • 21 Gnoth MJ, Buetehorn U, Muenster U et al. In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban. J Pharm Exp Ther 2011; 338: 372-380
    CrossrefPubMedGoogle Scholar
  • 22 Fachinformation Multaq®; Sanofi-Aventis; Stand 11/2013.
    PubMedGoogle Scholar
  • 23 Flaker G, Lopes RD, Hylek E et al. Amiodarone, Anticoagulation, and Clinical Events in Patients with Atrial Fibrillation: insights from the ARISTOTLE Trial. J Am Coll Cardiol 2014; 64: 1541-1550
    CrossrefPubMedGoogle Scholar
  • 24 Mendell J, Zahir H, Matsushima N et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 2013; 13: 331-342
    CrossrefPubMedGoogle Scholar
  • 25 Hariharan S, Madabushi R. Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmacol 2012; 52 (Suppl) 119S-125S
    CrossrefPubMedGoogle Scholar